We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Amgen, Cisco, Berkshire Hathaway, T. Rowe Price and McKesson
Read MoreHide Full Article
For Immediate Release
Chicago, IL –September 13, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amgen (AMGN - Free Report) , Cisco (CSCO - Free Report) , Berkshire Hathaway (BRK.B - Free Report) , T. Rowe Price (TROW - Free Report) and McKesson (MCK - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports for Amgen, Cisco and Berkshire Hathaway
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amgen, Cisco and Berkshire Hathaway. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Amgen’s shares have outperformed the Zacks Biomedical and Genetics industry on a year-to-date basis (0.6% vs. -1.4%). The Zacks analyst thinks that while Amgen’s newer drugs — Prolia, Xgeva, Blincyto, Kyprolis — will drive sales, biosimilar and brand competition for its legacy products will create pressure on sales in the second half.
Meanwhile, uptake of key drug, Repatha, has been slow due to payer restrictions. However, recently launched products, including Aimovig and Evenity, biosimilars and international expansion provide incremental growth opportunities.
Amgen is also progressing with its pipeline. In the past five years, Amgen has launched nine products, including two in new therapeutic areas. Amgen boasts a strong biosimilars pipeline, which could be an important long-term growth driver. The company’s restructuring plan is making it leaner and more cost efficient. Amgen’s shares have outperformed the industry so far this year.
Shares of Cisco have lost 4.9% in the past six months, outperforming the Zacks Computer Networking industry’s fall of 5.2%. The Zacks analyst believes that Cisco is benefiting from a solid security business. Strong contribution from Infrastructure Platforms and applications is a positive.
Moreover, order strength and improving traction of the subscription-based business model are tailwinds. Further, a strengthening collaboration portfolio, which includes Webex Teams, bodes well. Additionally, the acquisitions of Voicea and CloudCherry hold promise. Notably, shares of the company have outperformed the industry in the past year.
However, weakness in service provider business in China remains a concern. Further, stiff competition from Arista and Juniper in switching and routing verticals is likely to create pricing pressure and impact profitability. Also, increasing investments in product enhancements are likely to limit margin expansion at least in the near term.
BRK.B’s shares have gained 2.9% over the past six months, outperforming the Zacks Insurance - Property and Casualty industry’s rise of 2.5%.
The Zacks analyst believes that Berkshire Hathaway’s inorganic growth story remains impressive with strategic acquisitions. A strong cash position supports earnings-accretive bolt-on buyouts. Demand for utilities is expected drive earnings growth. Continued insurance business growth also increases float. Its non-insurance businesses are delivering improved results. A sturdy capital level provides further impetus.
However, exposure to catastrophe loss remains a concern as its property and casualty insurance business generates maximum return on equity. Huge capital expenses due to railroad operations pose concerns.
Other noteworthy reports we are featuring today include T. Rowe Price and McKesson.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Amgen, Cisco, Berkshire Hathaway, T. Rowe Price and McKesson
For Immediate Release
Chicago, IL –September 13, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amgen (AMGN - Free Report) , Cisco (CSCO - Free Report) , Berkshire Hathaway (BRK.B - Free Report) , T. Rowe Price (TROW - Free Report) and McKesson (MCK - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports for Amgen, Cisco and Berkshire Hathaway
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amgen, Cisco and Berkshire Hathaway. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Amgen’s shares have outperformed the Zacks Biomedical and Genetics industry on a year-to-date basis (0.6% vs. -1.4%). The Zacks analyst thinks that while Amgen’s newer drugs — Prolia, Xgeva, Blincyto, Kyprolis — will drive sales, biosimilar and brand competition for its legacy products will create pressure on sales in the second half.
Meanwhile, uptake of key drug, Repatha, has been slow due to payer restrictions. However, recently launched products, including Aimovig and Evenity, biosimilars and international expansion provide incremental growth opportunities.
Amgen is also progressing with its pipeline. In the past five years, Amgen has launched nine products, including two in new therapeutic areas. Amgen boasts a strong biosimilars pipeline, which could be an important long-term growth driver. The company’s restructuring plan is making it leaner and more cost efficient. Amgen’s shares have outperformed the industry so far this year.
(You can read the full research report on Amgen here >>>)
Shares of Cisco have lost 4.9% in the past six months, outperforming the Zacks Computer Networking industry’s fall of 5.2%. The Zacks analyst believes that Cisco is benefiting from a solid security business. Strong contribution from Infrastructure Platforms and applications is a positive.
Moreover, order strength and improving traction of the subscription-based business model are tailwinds. Further, a strengthening collaboration portfolio, which includes Webex Teams, bodes well. Additionally, the acquisitions of Voicea and CloudCherry hold promise. Notably, shares of the company have outperformed the industry in the past year.
However, weakness in service provider business in China remains a concern. Further, stiff competition from Arista and Juniper in switching and routing verticals is likely to create pricing pressure and impact profitability. Also, increasing investments in product enhancements are likely to limit margin expansion at least in the near term.
(You can read the full research report on Cisco here >>>).
BRK.B’s shares have gained 2.9% over the past six months, outperforming the Zacks Insurance - Property and Casualty industry’s rise of 2.5%.
The Zacks analyst believes that Berkshire Hathaway’s inorganic growth story remains impressive with strategic acquisitions. A strong cash position supports earnings-accretive bolt-on buyouts. Demand for utilities is expected drive earnings growth. Continued insurance business growth also increases float. Its non-insurance businesses are delivering improved results. A sturdy capital level provides further impetus.
However, exposure to catastrophe loss remains a concern as its property and casualty insurance business generates maximum return on equity. Huge capital expenses due to railroad operations pose concerns.
(You can read the full research report on BRK.B here >>>).
Other noteworthy reports we are featuring today include T. Rowe Price and McKesson.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.